These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
160 related items for PubMed ID: 12839704
21. Relationship with original pathogen in recurrence of acute otitis media after completion of amoxicillin/clavulanate: bacterial relapse or new pathogen. Kaur R, Casey JR, Pichichero ME. Pediatr Infect Dis J; 2013 Nov; 32(11):1159-62. PubMed ID: 23736142 [Abstract] [Full Text] [Related]
22. Role of Streptococcus pneumoniae and Haemophilus influenzae in the development of acute otitis media and otitis media with effusion in a gerbil model. Soriano F, Parra A, Cenjor C, Nieto E, García-Calvo G, Giménez MJ, Aguilar L, Ponte C. J Infect Dis; 2000 Feb; 181(2):646-52. PubMed ID: 10669350 [Abstract] [Full Text] [Related]
23. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media. Fenoll A, Aguilar L, Robledo O, Giménez MJ, Tarragó D, Granizo JJ, Gimeno M, Coronel P. J Antimicrob Chemother; 2007 Aug; 60(2):323-7. PubMed ID: 17562681 [Abstract] [Full Text] [Related]
25. Antimicrobial resistance among Streptococcus pneumoniae and Haemophilus influenzae isolates in the United Arab Emirates: 2004-2006. Senok A, Al-Zarouni M, Al-Najjar J, Nublusi A, Panigrahi D. J Infect Dev Ctries; 2007 Dec 01; 1(3):296-302. PubMed ID: 19734608 [Abstract] [Full Text] [Related]
26. Efficacy of Solithromycin (CEM-101) for Experimental Otitis Media Caused by Nontypeable Haemophilus influenzae and Streptococcus pneumoniae. Figueira M, Fernandes P, Pelton SI. Antimicrob Agents Chemother; 2016 Sep 01; 60(9):5533-8. PubMed ID: 27401563 [Abstract] [Full Text] [Related]
27. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. Harrison CJ, Woods C, Stout G, Martin B, Selvarangan R. J Antimicrob Chemother; 2009 Mar 01; 63(3):511-9. PubMed ID: 19174454 [Abstract] [Full Text] [Related]
29. Overview of newer antimicrobial formulations for overcoming pneumococcal resistance. Craig WA. Am J Med; 2004 Aug 02; 117 Suppl 3A():16S-22S. PubMed ID: 15360093 [Abstract] [Full Text] [Related]
30. Evaluation of coamoxiclav and other antibiotics against S pneumoniae and H influenae from paediatric cases of acute respiratory infections. Krishnan P, Rajendran P, Sambandan AP, Anitha C, Chavda RK, Khobragade KJ. J Indian Med Assoc; 2011 Apr 02; 109(4):241-2, 244. PubMed ID: 22187795 [Abstract] [Full Text] [Related]
31. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Berry V, Thorburn CE, Knott SJ, Woodnutt G. Antimicrob Agents Chemother; 1998 Dec 02; 42(12):3193-9. PubMed ID: 9835514 [Abstract] [Full Text] [Related]
32. Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media. Easton J, Noble S, Perry CM. Drugs; 2003 Dec 02; 63(3):311-40. PubMed ID: 12534334 [Abstract] [Full Text] [Related]
33. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B. J Antimicrob Chemother; 2004 Jan 02; 53 Suppl 1():i3-20. PubMed ID: 14726431 [Abstract] [Full Text] [Related]
34. Eradication of Streptococcus pneumoniae in the nasopharyngeal flora of children with acute otitis media after amoxicillin-clavulanate therapy. Brook I, Gober AE. Antimicrob Agents Chemother; 2004 Apr 02; 48(4):1419-21. PubMed ID: 15047558 [Abstract] [Full Text] [Related]
36. [Pharmacodynamic basis for the use of amoxicillin-clavulanic acid in respiratory infections due to Streptococcus pneumoniae: In vitro studies in an experimental model]. Gómez-Lus ML, García Y, Valero E, Amores R, Fuentes F. Rev Esp Quimioter; 2000 Sep 02; 13(3):306-13. PubMed ID: 11086282 [Abstract] [Full Text] [Related]
37. Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model. MacGowan AP, Noel AR, Rogers CA, Bowker KE. Antimicrob Agents Chemother; 2004 Jul 02; 48(7):2599-603. PubMed ID: 15215115 [Abstract] [Full Text] [Related]
38. Amoxicillin-sulbactam versus amoxicillin-clavulanic acid for the treatment of non-recurrent-acute otitis media in Argentinean children. Casellas JM, Israele V, Marín M, Ishida MT, Heguilen R, Soutric J, Arenoso H, Sibbald A, Stamboulian D. Int J Pediatr Otorhinolaryngol; 2005 Sep 02; 69(9):1225-33. PubMed ID: 16061111 [Abstract] [Full Text] [Related]
39. Efficacy/safety of amoxicillin/clavulanate in adults with bacterial rhinosinusitis. Anon JB, Berkowitz E, Breton J, Twynholm M. Am J Otolaryngol; 2006 Sep 02; 27(4):248-54. PubMed ID: 16798401 [Abstract] [Full Text] [Related]
40. Eradication of pathogens from the nasopharynx after therapy of acute maxillary sinusitis with low- or high-dose amoxicillin/clavulanic acid. Brook I, Foote PA, Hausfeld JN. Int J Antimicrob Agents; 2005 Nov 02; 26(5):416-9. PubMed ID: 16226017 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]